Carisma Therapeutics Inc (NASDAQ: CARM)’s stock price has gone decline by -9.52 in comparison to its previous close of 1.26, however, the company has experienced a -5.00% decrease in its stock price over the last five trading days. prnewswire.com reported 2024-07-01 that Appointment of David Scadden, M.D. and Marella Thorell Resignation of Regina Hodits and Björn Odlander PHILADELPHIA, July 1, 2024 /PRNewswire/ — Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Marella Thorell and David Scadden, M.D.
Is It Worth Investing in Carisma Therapeutics Inc (NASDAQ: CARM) Right Now?
The 36-month beta value for CARM is at 1.54. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CARM is 20.17M, and currently, shorts hold a 9.69% of that float. The average trading volume for CARM on July 19, 2024 was 799.41K shares.
CARM’s Market Performance
CARM’s stock has seen a -5.00% decrease for the week, with a 10.68% rise in the past month and a -32.54% fall in the past quarter. The volatility ratio for the week is 9.95%, and the volatility levels for the past 30 days are at 11.73% for Carisma Therapeutics Inc The simple moving average for the last 20 days is -7.65% for CARM’s stock, with a simple moving average of -49.04% for the last 200 days.
Analysts’ Opinion of CARM
Many brokerage firms have already submitted their reports for CARM stocks, with BTIG Research repeating the rating for CARM by listing it as a “Buy.” The predicted price for CARM in the upcoming period, according to BTIG Research is $6 based on the research report published on April 11, 2024 of the current year 2024.
CapitalOne, on the other hand, stated in their research note that they expect to see CARM reach a price target of $10. The rating they have provided for CARM stocks is “Overweight” according to the report published on October 03rd, 2023.
Evercore ISI gave a rating of “Outperform” to CARM, setting the target price at $12 in the report published on July 06th of the previous year.
CARM Trading at -11.66% from the 50-Day Moving Average
After a stumble in the market that brought CARM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.11% of loss for the given period.
Volatility was left at 11.73%, however, over the last 30 days, the volatility rate increased by 9.95%, as shares surge +10.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.53% lower at present.
During the last 5 trading sessions, CARM fell by -5.00%, which changed the moving average for the period of 200-days by -73.05% in comparison to the 20-day moving average, which settled at $1.2400. In addition, Carisma Therapeutics Inc saw -61.09% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CARM
Current profitability levels for the company are sitting at:
- -5.66 for the present operating margin
- 0.66 for the gross margin
The net margin for Carisma Therapeutics Inc stands at -5.39. The total capital return value is set at -1.41. Equity return is now at value -167.51, with -70.64 for asset returns.
Based on Carisma Therapeutics Inc (CARM), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at -10.44. The debt to equity ratio resting at 0.69. The interest coverage ratio of the stock is -103.61.
Currently, EBITDA for the company is -80.47 million with net debt to EBITDA at 0.6. When we switch over and look at the enterprise to sales, we see a ratio of -0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.64.
Conclusion
In conclusion, Carisma Therapeutics Inc (CARM) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
